{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:35:48Z","timestamp":1791192948689,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.vaccine.2007.08.005","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T10:57:05Z","timestamp":1188212225000},"page":"7429-7435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Shigeru","family":"Yutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyogo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.08.005_bib1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/jvi.69.4.2462-2470.1995","article-title":"Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules","volume":"69","author":"Battegay","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1365-2893.2000.00221.x","article-title":"Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States","volume":"7","author":"Blatt","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vaccine.2007.08.005_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI117694","article-title":"Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif","volume":"95","author":"Cerny","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2007.08.005_bib4","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1002\/hep.1840360718","article-title":"Treatment of chronic hepatitis C: a systematic review","volume":"36","author":"Chander","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2007.08.005_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/rmv.466","article-title":"Hepatitis C virus and the immune system: a concise review","volume":"15","author":"Gremion","year":"2005","journal-title":"Rev Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.08.005_bib6","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2007.08.005_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0161-5890(01)00083-9","article-title":"Perspectives: towards a peptide-based vaccine against hepatitis C virus","volume":"38","author":"Hunziker","year":"2001","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib8","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.87.24.9524","article-title":"Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis","volume":"87","author":"Kato","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.08.005_bib9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0168-8278(01)00041-1","article-title":"A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection","volume":"34","author":"Kurokohchi","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-1117-3","article-title":"Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses","volume":"10","author":"Mine","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2007.08.005_bib11","first-page":"121","article-title":"Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen","volume":"25","author":"Mochizuki","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jmv.10349","article-title":"Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers","volume":"70","author":"Nakamoto","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib13","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2007.08.005_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pros.20157","article-title":"Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients","volume":"63","author":"Noguchi","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2007.08.005_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1872-034X.2007.00018.x","article-title":"Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b+ HLA-A24+ patients","volume":"37","author":"Takao","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1016\/j.vaccine.2007.08.005_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/75063","article-title":"Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C","volume":"6","author":"Takaki","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2007.08.005_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.hepres.2005.06.003","article-title":"Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b+ HLA-A24+ patients","volume":"32","author":"Tamura","year":"2005","journal-title":"Hepatol Res"},{"key":"10.1016\/j.vaccine.2007.08.005_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/1521-4141(200201)32:1<144::AID-IMMU144>3.0.CO;2-X","article-title":"Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals","volume":"32","author":"Vertuani","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cellimm.2006.07.009","article-title":"Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients","volume":"241","author":"Wang","year":"2006","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2249.2002.01840.x","article-title":"Cellular immune responses against hepatitis C virus: the evidence base","volume":"128","author":"Ward","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2007.08.005_bib21","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-05-0559","article-title":"Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma","volume":"11","author":"Yajima","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0700919X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0700919X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:15:11Z","timestamp":1759400111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0700919X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":21,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0264410X0700919X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}